Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema

NCT05324774 ·Status: UNKNOWN ·Phase: PHASE3

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

NCT02633852 ·Status: COMPLETED ·Phase: PHASE4

A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

NCT06422507 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan

NCT04288232 ·Status: COMPLETED ·Phase: PHASE3

Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection

NCT03453281 ·Status: COMPLETED ·Phase: PHASE4

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

NCT04429503 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

NCT02924311 ·Status: COMPLETED

BEOVU Versus Eylea in the Treatment of Diabetic Macular Edema

NCT04955171 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

NCT05511038 ·Status: COMPLETED ·Phase: PHASE4

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

NCT00789477 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection

NCT03297684 ·Status: UNKNOWN

Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

NCT01988246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema

NCT04739306 ·Status: COMPLETED ·Phase: PHASE3

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

NCT06099184 ·Status: COMPLETED ·Phase: PHASE2

Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage

NCT04153253 ·Status: COMPLETED ·Phase: PHASE4

Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study)

NCT03394573 ·Status: TERMINATED

Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema

NCT02874859 ·Status: COMPLETED

A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03481660 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement

NCT01783886 ·Status: COMPLETED ·Phase: PHASE3

Intravitreal Aflibercept Injection in Vision Impairment Due to DME

NCT01331681 ·Status: COMPLETED ·Phase: PHASE3

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

NCT06205979 ·Status: RECRUITING ·Phase: EARLY_PHASE1

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema

NCT06116916 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN

NCT02630277 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

NCT03161912 ·Status: COMPLETED